Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-042376 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001104659-22-039490 Act: 33 Size: 16 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-22-004615 Act: 34 Size: 12 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-22-004603 Act: 34 Size: 441 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 5.07 Accession Number: 0001104659-22-037550 Act: 34 Size: 195 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-031514 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-031520 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-029489 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-029492 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-22-025691 Act: 34 Size: 492 KB 网页链接